PBA
AUTL

Paradigm Biocapital Advisors’s Autolus Therapeutics AUTL Stock Holding History

Paradigm Biocapital Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,425,803
Closed -$41M – 37
2024
Q1 		$41M Sell
6,425,803
-6,185,532
-49% -$38.6M 1.44% 22
2023
Q4 		$81.2M Sell
12,611,335
-1,795,447
-12% -$6.85M 3.8% 13
2023
Q3 		$33.6M Buy
14,406,782
+5,189,632
+56% +$14.8M 2.28% 18
2023
Q2 		$21.9M Buy
+9,217,150
New +$21.9M 1.7% 24

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paradigm Biocapital Advisors's AUTL Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 6,425,803 shares — an estimated $41M sold.

Paradigm Biocapital Advisors first reported a position in AUTL in Q2 2023 and held it in 4 quarters. The position peaked at $81.2M in Q4 2023. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 6,425,803 Autolus Therapeutics shares in Q2 2024, an estimated $41M.
  • Paradigm Biocapital Advisors first reported a position in Autolus Therapeutics in Q2 2023 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's Autolus Therapeutics position peaked at $81.2M in Q4 2023.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.